

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: DIET DRUGS : MDL DOCKET NO. 1203
(PHENTERMINE, FENFLURAMINE, :
DEXFENFLURAMINE) PRODUCTS :
LIABILITY LITIGATION :
: :
THIS DOCUMENT RELATES TO: :
: :
SHEILA BROWN, et al. :
: :
v. :
: :
AMERICAN HOME PRODUCTS :
CORPORATION : CIVIL ACTION NO. 99-20593

PRETRIAL ORDER NO. 3134

AND NOW, on this 19th day of November, 2003, for the reasons set forth in the Memorandum accompanying Pretrial Order No. 3123, it is hereby ORDERED that:

(1) the plaintiff, Crystall Gatlin, and her agents, attorneys, and derivative claimants are ENJOINED in the case of Gatlin v. American Home Products Corp., et al., No. 2003-4007, pending in Orleans Parish, Louisiana, from introducing any evidence, making any statements before or argument to the court or jury related directly or indirectly to:

- (a) punitive, exemplary, or multiple damages, however described;
- (b) malicious, wanton, or other similar conduct of Wyeth, however described;
- (c) or any medical condition of plaintiffs caused by Wyeth other than left-sided aortic valve

regurgitation or pulmonary hypertension
secondary to aortic valve regurgitation.

(2) without limitation as to the scope of the injunction set forth in ¶ 1, the plaintiff, Crystall Gatlin, and her agents, attorneys, and derivative claimants are ENJOINED in the case of Gatlin v. American Home Products Corp., et al., No. 2003-4007, pending in Orleans Parish, Louisiana, from introducing any evidence, making any statements before or argument to the court or jury related directly or indirectly to:


- (a) Wyeth's profits, size, or financial condition;
- (b) the amount or size of Wyeth's sales of diet drugs or other products;
- (c) Wyeth's marketing or promotion of diet drugs to the extent that Wyeth placed marketing or promotion ahead of health or safety concerns;
- (d) any deception or any destruction, hiding, overwriting, or deliberate miscoding of documents or information by Wyeth;
- (e) any involvement by Wyeth in the ghostwriting of articles;
- (f) primary pulmonary hypertension ("PPH");
- (g) neurotoxicity;
- (h) any disease, illness, or condition, or persons suffering from any disease, illness, or condition caused by Redux or Pondimin

except for left-sided valvular heart disease or pulmonary hypertension secondary to left-sided valvular heart disease; and

- (i) the "four cases label" for Pondimin and the "black box warning" for Redux in 1995 and 1996; and

(3) the parties shall deliver forthwith to the state trial judge a copy of this Pretrial Order.

BY THE COURT:



J.